Dr. Mickey Kim Joins Canaan Partners as Principal in Firm's East Coast Office

Share Article

Focused on Investments in Biopharmaceuticals, Medical Device, Healthcare Services, and Diagnostics in the U.S. and Asia.

Mickey brings to Canaan a unique mix of investing, entrepreneurial, consulting, and technical experience in both the U.S. and Asia

Canaan Partners, a $2.3 billion global venture capital firm, today announced that Mickey Kim, MD has joined the firm as a Principal in its Westport, CT office. Dr. Kim will work with Canaan's global teams to identify healthcare trends and pursue investment opportunities, particularly in the biopharmaceutical, medical device, healthcare services, and diagnostic sectors in the U.S. and Asia.

"Mickey brings to Canaan a unique mix of investing, entrepreneurial, consulting, and technical experience in both the U.S. and Asia," said Stephen Bloch, venture partner at Canaan. "Our healthcare investment team has an outstanding track record with nine positive exits in the past three years. Mickey's unique background will help us to build an even stronger global investment portfolio, as we continue to invest in companies that are innovators in the healthcare field targeting unmet medical needs worldwide. We are very fortunate to have attracted him to our team."

Prior to joining Canaan, Dr. Kim co-founded Pacific Point Ventures, a venture capital fund investing in biotechnology service companies in Asia, and was a Principal at BioVentures Investors, a venture capital fund investing in biopharmaceutical and medical device companies in the U.S. He also served as a strategy consultant at McKinsey & Company and CSC Healthcare, and co-founded an Asian technology venture capital fund. Dr. Kim earned his MD degree from Northwestern University and an MBA from the JL Kellogg Graduate School of Management. He also holds an AB in History, Philosophy, Social Studies of Science and Medicine from the University of Chicago.

"I am delighted to join Canaan's healthcare investment team, a group that has established a strong track record of success," said Dr. Kim. "I have known Canaan for the past five years and feel very fortunate to join a cohesive team that takes a rather thoughtful, strategic, and hands on approach to investing."

About Canaan Partners:
Canaan Partners invests in visionary entrepreneurs and provides them the networks, insights and operational guidance required to build high-performance technology and healthcare companies. For 20 years, they have taken an active and committed role in the companies in which they invest, and have completed more than 65 mergers and acquisitions and 51 IPOs. With $2.3 billion under management and a worldwide footprint, the firm's healthcare team is committed to catalyzing the development of biotechnology, medical device, diagnostic and therapeutics companies that are revolutionizing the practice of medicine. Among its recent successes are Dexcom Inc., the largest diagnostic IPO of 2006, and Cerexa Inc., the largest private biotech merger and acquisition in history. Other recent Canaan healthcare investments include Amicus Therapeutics, Chimerix, Inc., ReVision Optics, Inc., and Transoma Medical, Inc. Canaan is headquartered in Menlo Park, California and also has offices in Connecticut, India and Israel. For more information visit: http://www.canaan.com.

Contact:
Erin McMahon-Lyman
Marketing Alchemist
Phone (510) 649-1390

Gina Vakili
Canaan Partners
Phone (650) 854-8092

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Gina Vakili
Visit website